antidiabetic drugs

Browse trials
Matrix  

Albiglutidediabetes type 2, in patients inadequately controlled on metformin vs placebo (add on MET)

all NS
Albiglutidediabetes type 2, in patients inadequately controlled on monotherapy vs placebo (add on MET)

all NS
Dapagliflozindiabetes type 2, in patients inadequately controlled on metformin vs placebo (add on MET)

all NS
Dapagliflozindiabetes type 2, in patients inadequately controlled on monotherapy vs placebo (add on MET)

all NS
Pioglitazonediabetes type 2, in patients inadequately controlled with insulin vs placebo (add on insulin)

all NS
Alogliptindiabetes type 2, in patients inadequately controlled on metformin vs placebo (add on MET)

all NS
Alogliptindiabetes type 2, in patients inadequately controlled on monotherapy vs placebo (add on MET)

all NS
Linagliptindiabetes type 2, in patients inadequately controlled on monotherapy vs placebo (add on SU)

all NS
Linagliptin vs glimepiride (add on MET)

all NS
Linagliptindiabetes type 2, in patients insufficiently controlled on SU vs placebo (add on SU)

all NS
Linagliptindiabetes type 2, in Patients inadequately controlled on MET+SU therapy vs Metformin + sulfonylurea

all NS
Linagliptindiabetes type 2, in patients with insufficient glycaemic control with bitherapy vs Metformin + sulfonylurea

all NS
Linagliptindiabetes type 2, in drug naïve patients vs placebo

all NS
Linagliptindiabetes type 2, in patients inadequately controlled on metformin vs glimepiride (add on MET)

all NS
Saxagliptindiabetes type 2, in patients inadequately controlled on metformin vs placebo (add on MET)

all NS
Saxagliptin vs sitagliptin (add on MET)

all NS
Saxagliptindiabetes type 2, in patients inadequately controlled on monotherapy vs placebo (add on MET)

all NS
Saxagliptin vs placebo (add on TZD)

all NS
Saxagliptin vs sitagliptin (add on MET)

all NS
Saxagliptindiabetes type 2, in in patients inadequately controlled on standard therapy vs placebo (add on current treatment)

all NS
Saxagliptindiabetes type 2, in drug naïve patients vs placebo (monotherapy)

all NS
Saxagliptindiabetes type 2, in patients inadequately controlled with insulin vs placebo (add on insulin)

all NS
Saxagliptindiabetes type 2, in patients inadequately controlled on TZD vs placebo (add on TZD)

all NS
Sitagliptindiabetes type 2, in patients inadequately controlled on metformin vs placebo (add on MET)

all NS
Sitagliptindiabetes type 2, in patients inadequately controlled on monotherapy vs placebo (add on MET)

all NS
Sitagliptin vs placebo (on top PIO)

Adverse events leading to treatment discontinuation by 459% adverse event
Sitagliptindiabetes type 2, in patients with insufficient glycaemic control with bitherapy vs placebo (on-top glimepiride+/- metformine)

all NS
Vildagliptindiabetes type 2, in patients inadequately controlled on metformin vs placebo (add on MET)

all NS
Vildagliptin vs Sulfonylurea (add on to MET)

all NS
Vildagliptin vs pioglitazone (add on MET)

all NS
Vildagliptindiabetes type 2, in patients inadequately controlled on monotherapy vs placebo (add on insulin)

Adverse events leading to treatment discontinuation by 850% adverse event
Vildagliptin vs placebo (add on MET)

all NS
Vildagliptin vs placebo (on top pioglitazone)

all NS
Vildagliptin vs Sulfonylurea (add on to MET)

all NS
Vildagliptin vs pioglitazone (add on MET)

all NS
Vildagliptin vs placebo (add on TZD)

all NS
Vildagliptindiabetes type 2, in patients inadequately controlled with insulin vs placebo (add on insulin)

Adverse events leading to treatment discontinuation by 850% adverse event
Vildagliptindiabetes type 2, in patients inadequately controlled on TZD vs placebo (on top pioglitazone)

all NS
Vildagliptin vs placebo (add on TZD)

all NS
Exenatidediabetes type 2, in patients with insufficient glycaemic control with bitherapy vs weekly exenatide

all NS
Exenatide vs placebo (add on MER+/-SU)

all NS
Exenatide vs placebo (add on MET+/-SU)

all hypoglycemia by 292% adverse event

treatment-emergent adverse events (TEAEs) by 58% adverse event

A CHANGER by 2825% adverse event

vomiting by 7336% adverse event
Exenatide vs placebo (add on SU+/-MET/TZD)

all NS
Exenatide vs placebo (add on SU+MET)

all hypoglycemia by 277% adverse event

A CHANGER by 111% adverse event

vomiting by 219% adverse event

diarrhoea by 110% adverse event
Exenatide vs placebo (add on TZD+/-MET)

A CHANGER by 161% adverse event

vomiting by 1381% adverse event
Exenatide vs insulin (add on SU+MET)

A CHANGER by 563% adverse event

vomiting by 364% adverse event

diarrhoea by 184% adverse event
Exenatide vs insulin (add on SU/MET)

all NS
Exenatide vs insulin BIAsp twice daily add on SU+MET

A CHANGER by 8134% adverse event

vomiting by 366% adverse event

diarrhoea by 371% adverse event
Exenatidediabetes type 2, in patients inadequately controlled with insulin vs placebo (add on insulin)

A CHANGER by 399% adverse event

vomiting by 345% adverse event

diarrhoea by 123% adverse event
Exenatide vs insulin (add on SU+MET)

A CHANGER by 563% adverse event

vomiting by 364% adverse event

diarrhoea by 184% adverse event
Exenatide vs insulin (add on SU/MET)

A CHANGER by 838% adverse event

vomiting by 220% adverse event
Exenatide vs insulin BIAsp twice daily add on SU+MET

A CHANGER by 8134% adverse event

vomiting by 366% adverse event

diarrhoea by 371% adverse event
Exenatide vs insulin glargine

A CHANGER by 857% adverse event

diarrhoea by 139% adverse event
Exenatide vs insulin glargine (add on MET/SU)

all NS
Exenatidediabetes type 2, in Patients inadequately controlled on MET+SU therapy vs placebo (add on SU+MET)

all hypoglycemia by 277% adverse event

A CHANGER by 111% adverse event

vomiting by 219% adverse event

diarrhoea by 110% adverse event
Exenatide vs insulin (add on SU+MET)

A CHANGER by 563% adverse event

vomiting by 364% adverse event

diarrhoea by 184% adverse event
Exenatide vs insulin BIAsp twice daily add on SU+MET

A CHANGER by 8134% adverse event

vomiting by 366% adverse event

diarrhoea by 371% adverse event
Exenatidediabetes type 2, in patients inadequately controlled on metformin vs placebo (add on MET)

all NS
Exenatide vs placebo (add on MET+/-SU)

all hypoglycemia by 292% adverse event

treatment-emergent adverse events (TEAEs) by 58% adverse event

A CHANGER by 2825% adverse event

vomiting by 7336% adverse event
Exenatidediabetes type 2, in patients inadequately controlled on monotherapy vs placebo (add on MER+/-SU)

all NS
Exenatide vs placebo (add on MET)

all NS
Exenatide vs placebo (add on MET+/-SU)

all hypoglycemia by 292% adverse event

treatment-emergent adverse events (TEAEs) by 58% adverse event

A CHANGER by 2825% adverse event

vomiting by 7336% adverse event
Exenatide vs placebo (add on SU)

A CHANGER by 436% adverse event

vomiting by 294% adverse event
Exenatide vs exenatide before breakfast and dinner

all NS
Exenatide vs insulin glargine (add on MET/SU)

all NS
Liraglutidediabetes type 2, in patients inadequately controlled on monotherapy vs placebo (add on MET)

all NS
Liraglutide vs placebo (add on SU)

A CHANGER by 330% adverse event
Liraglutide vs placebo (add on SU+MET)

A CHANGER by 297% adverse event

diarrhoea by 280% adverse event
Liraglutide vs glimepiride (add on MET)

all NS
Liraglutide vs insulin glargine (add on SU+MET)

A CHANGER by 976% adverse event

vomiting by 1413% adverse event

diarrhoea by 673% adverse event
Liraglutide vs rosiglitazone (add on SU)

all NS
Liraglutide vs glibenclamide

all NS
Liraglutide vs sitagliptin

A CHANGER by 421% adverse event

vomiting by 110% adverse event

diarrhoea by 103% adverse event
Liraglutidediabetes type 2, in patients with insufficient glycaemic control with bitherapy vs placebo (add on TZD+MET)

all NS
Liraglutide vs exenatide on top MET/SU/MET+SU

severe adverse events by 180% adverse event
Liraglutidediabetes type 2, in Patients inadequately controlled on MET+SU therapy vs placebo (add on SU+MET)

A CHANGER by 297% adverse event

diarrhoea by 280% adverse event
Liraglutide vs insulin glargine (add on SU+MET)

A CHANGER by 976% adverse event

vomiting by 1413% adverse event

diarrhoea by 673% adverse event
Liraglutide vs exenatide on top MET/SU/MET+SU

severe adverse events by 180% adverse event
Liraglutidediabetes type 2, in patients inadequately controlled on metformin vs placebo (add on MET)

all NS
Liraglutide vs glimepiride (add on MET)

all NS
Liraglutide vs sitagliptin

A CHANGER by 421% adverse event

vomiting by 110% adverse event

diarrhoea by 103% adverse event
Taspoglutidediabetes type 2, in patients inadequately controlled on metformin vs placebo (add on MET)

all NS
Taspoglutide vs placebo

all NS
Taspoglutidediabetes type 2, in patients inadequately controlled on monotherapy vs placebo (add on MET)

all NS
Taspoglutide vs placebo

all NS
Lixisenatide diabetes type 2, in patients inadequately controlled on metformin vs placebo (add on MET)

all NS
Lixisenatide diabetes type 2, in patients inadequately controlled on monotherapy vs placebo (add on MET)

all NS
Lixisenatide diabetes type 2, in patients inadequately controlled with insulin vs placebo (add on basal insulin)

all NS
Mitiglinidediabetes type 2, in all types of patients vs nateglinide

all NS
Mitiglinide vs on top insulin glargine

all NS
Mitiglinide vs placebo (on top pioglitazone)

all NS
Mitiglinidediabetes type 2, in patients inadequately controlled on monotherapy vs placebo (on top pioglitazone)

all NS
Nateglinidediabetes type 2, in all types of patients vs repaglinide

all NS
Nateglinide vs placebo

all NS
Nateglinide vs gliclazide (add on MET)

all NS
Nateglinidediabetes type 2, in patients inadequately controlled on metformin vs gliclazide (add on MET)

all NS
Nateglinidediabetes type 2, in patients inadequately controlled on monotherapy vs gliclazide (add on MET)

all NS
Repaglinide diabetes type 2, in all types of patients vs glibenclamide

all NS
Repaglinide vs glipizide

all NS
Repaglinide vs metformin

all NS
Repaglinide vs on top pioglitazone

all NS
Repaglinide vs on top rosiglitazone

all NS
Repaglinide vs on top troglitazone

all NS
Repaglinide vs placebo (on top bedtime NPH-insulin)

all NS
Repaglinide vs control (add on MET)

all NS
Repaglinide vs placebo

all NS
Repaglinide diabetes type 2, in patients inadequately controlled on metformin vs control (add on MET)

all NS
Repaglinide diabetes type 2, in patients inadequately controlled on monotherapy vs control (add on MET)

all NS
Glipizidediabetes type 2, in all types of patients vs control (add on MET)

all NS
Glipizide vs glyburide

all NS
Glipizide vs placebo

all NS
Glipizidediabetes type 2, in patients inadequately controlled on monotherapy vs control (add on MET)

all NS
Glipizide vs glyburide

all NS
Glipizidediabetes type 2, in patients insufficiently controlled on SU vs glyburide

all NS
Glyburidediabetes type 2, in all types of patients vs c (add on MET)

all NS
Glyburide vs control (add on MET)

all NS
Glyburide vs placebo

all NS
Glyburidediabetes type 2, in patients inadequately controlled on monotherapy vs control (add on MET)

all NS
Glyburide vs placebo

all NS
Glimeripidediabetes type 2, in all types of patients vs placebo

all NS
Glimeripide vs placebo (add on insulin)

all NS
Glimeripide vs placebo (add on MET)

all NS
Glimeripide vs gliclazide

all NS
Glimeripide vs glibenclamide

all NS
Glimeripide vs gliclazide or glibenclamide

all NS
Glimeripide vs glimepiride bid

all NS
Glimeripide vs glipizide

all NS
Glimeripide vs glyburide

all NS
Glimeripidediabetes type 2, in patients inadequately controlled on monotherapy vs placebo (add on insulin)

all NS
Glimeripide vs placebo (add on MET)

all NS
Glimeripide vs gliclazide or glibenclamide

all NS
Glimeripidediabetes type 2, in patients inadequately controlled on metformin vs placebo (add on MET)

all NS
Rosiglitazonediabetes type 2, in patients inadequately controlled with insulin vs

all NS
Rosiglitazone vs placebo

all NS
Rosiglitazone vs placebo (add on insulin)

all NS

 


- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons